Anti-EMP3 polyclonal antibody

Background To identify independently prognostic gene panel in patients with glioblastoma (GBM). Materials and methods The Cancer Genome Atlas (TCGA)-GBM was used as a training set and a test set. GSE13041 was used as a validation set. Survival associated differentially expression genes (DEGs), derived between GBM and normal brain tissue, was obtained using univariate Cox proportional hazards regression model and then was included in a least absolute shrinkage and selection operator penalized Cox proportional hazards regression model. Thus, a 4-gene prognostic panel was developed based on the risk score for each patient in that model. The prognostic role of the 4-gene panel was validated using univariate and multivariable Cox proportional hazards regression model. Results A total of 686 patients with GBM were included in our study; 724 DEGs was identified, 133 of which was significantly correlated with the overall survival (OS) of patients with GBM. A 4-gene panel including NMB, RTN1, GPC5, and epithelial membrane protein 3 (EMP3) was developed. Kaplan-Meier survival analysis suggested that patients in the 4-gene panel low risk group had significantly better OS than those in the 4-gene panel high risk group in the training set (hazard ratio [HR] = 0.3826; 95% confidence interval [CI]: 0.2751-0.532; P < 0.0001), test set (HR = 0.718; 95% CI: 0.5282-0.9759; P = 0.033) and the independent validation set (HR = 0.6898; 95% CI: 0.4872-0.9766; P = 0.035). Both univariate and multivariable Cox proportional hazards regression analysis suggested that the 4-gene panel was independent prognostic factor for GBM in the training set. Conclusion We developed and validated 4-gene panel that was independently correlated with the survival of patients with GBM.

t(8;21)(q22;q22) acute myelogenous leukemia (AML) is morpho-logically characterized by a continuum of heterogeneous leukemia cells from myeloblasts to differentiated myeloid elements. Thus, t(8;21) AML is an excellent model for studying heterogeneous cell populations and cellular evolution during disease progression. Using integrative analyses of immunophenotype, RNA-sequencing (RNA-seq), and single-cell RNA-sequencing (scRNA-seq), we identi-fied three distinct intrapatient leukemic cell populations that were arrested at different stages of myeloid differentiation: CD34*CD117dim blasts, CD34*CD117bri blasts, and abnormal myeloid cells with partial maturation (AM). CD117 is also known as c-KIT protein. CD34*CD117dim cells were blocked in the G0/G1 phase at disease onset, presenting with the regular morphology of myeloblasts showing features of granulocyte-monocyte progenitors (GMP), and were drug-resistant to chemotherapy. Genes associated with cell migration and adhe-sion (LGALS1, EMP3, and ANXA2) were highly expressed in the CD34*CD117dim population. CD34*CD117bri blasts were blocked a bit later than the CD34*CD117dim population in the hematopoietic differentiation stage and displayed high proliferation ability. AM cells, which bear abnormal myelocyte morphology, especially over -expressed granule genes AZU1, ELANE, and PRTN3 and were sensi-tive to chemotherapy. scRNA-seq at different time points identified CD34*CD117dim blasts as an important leukemic cluster that ex-panded at postrelapse refractory stage after several cycles of che-motherapy. Patients with t(8;21) AML with a higher proportion of CD34*CD117dim cells had significantly worse clinical outcomes than those with a lower CD34*CD117dim proportion. Univariate and mul-tivariate analyses identified CD34*CD117dim proportion as an inde-pendent factor for poor disease outcome. Our study provides evidence for the multidimensional heterogeneity of t(8;21)AML and may offer new tools for future disease stratification.